Tatva Chintan Pharma IPO is second-most subscribed this year at 180 times


Tatva Chintan Pharma Chem’s has garnered 180 times subscription, making it the second-most subscribed offering of the year. The 3.26-million share offering garnered bids for 588 million shares, generating demand worth Rs 63,713 crore. The institutional investor portion of the was subscribed 185 times, the high networth individual (HNI) portion was subscribed 512 time and the retail portion garnered 35 times subscription. In March, the of MTAR Technologies had garnered 200 times subscription.

Tatva Chintan is a chemical manufacturing company that produces structure-directing agents (SDAs), phase transfer catalyst (PTCs), electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates alongside other specialty chemicals. The company’s Rs 500-crore IPO consisted of 225 crore fresh fund raise and Rs 275 crore offer for sale. The price band for the IPO was Rs 1,073-1,083 per share. At the top-end, the company will have market capitalisation of Rs 2,400 crore. Following the IPO, the promoter holding in the company will decline from 100 per cent to 79.2 per cent.

Most brokerages had recommended their clients to subscribe to the IPO citing reasonable valuations.

At the upper price band of Rs 1,083, the company was valued at 46 times its FY21 earnings on a diluted basis. Listed companies in the space trade at much richer valuations. Navin Fluorine International is valued at 74 times its FY21 earnings, while Alkyl Amines Chemicals is valued at 66 times, said a note by Marwadi Financial Services.

Category Subscription

Source: NSE, BSE

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Source link


Please enter your comment!
Please enter your name here